User profiles for Gérard Zalcman
 | ZALCMAN GerardPU-PH, Université Paris Cité; U830 Inserm Verified email at aphp.fr Cited by 37483 |
Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non …
8000 Background: Personalized medicine is now a reality for advanced NSCLC pts on the
basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French …
basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French …
[HTML][HTML] Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on …
Following the American National Lung Screening Trial results in 2011 a consortium of
French experts met to edit a statement. Recent results of other randomized trials gave the …
French experts met to edit a statement. Recent results of other randomized trials gave the …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
…, DR Gandara, BP Levy, SG Nair, G Zalcman… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
J Mazières, G Zalcman, L Crinò, P Biondani… - Journal of clinical …, 2015 - ascopubs.org
Purpose Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1
rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and …
rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. Patients and …
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 …
E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon… - The Lancet, 2011 - thelancet.com
Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical
responses in a sizable minority of cancer patients. We found that primary resistance to ICIs …
responses in a sizable minority of cancer patients. We found that primary resistance to ICIs …
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
…, P Aanur, A Oukessou, C Baudelet, G Zalcman - The Lancet, 2021 - thelancet.com
Background Approved systemic treatments for malignant pleural mesothelioma (MPM) have
been limited to chemotherapy regimens that have moderate survival benefit with poor …
been limited to chemotherapy regimens that have moderate survival benefit with poor …
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label …
G Zalcman, J Mazieres, J Margery, L Greillier… - The Lancet, 2016 - thelancet.com
Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic …
Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC)
for known oncogenic drivers is recommended during routine care. Nationally, …
for known oncogenic drivers is recommended during routine care. Nationally, …
Pulmonary arterial hypertension in patients treated by dasatinib
Background— The French pulmonary hypertension (PH) registry allows the survey of
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …
epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have …
